Dual-Encapsulation of Paclitaxel and Quercetin in Solid Lipid Nanoparticles for Enhanced Pulmonary Cancer Therapy: In Vitro and In Vivo Evaluation
نویسندگان
1 Department of Internal Disease, Endocrinology, Tashkent State Medical Institute, Tashkent, Republic of Uzbekistan
2 Department of Internal Diseases No. 3, Samarkand State Medical University, Samarkand, Uzbekistan
3 Department of Faculty and Hospital Surgery, Fergana Medical Institute of Public Health, Fergana, Uzbekistan
4 Jizzakh Branch of the National University of Uzbekistan, Jizzakh City, Uzbekistan
5 Department of Surgical Diseases in Family Medicine, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
6 Department of Pediatric Dentistry, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Republic of Uzbekistan
7 Tashkent State Technical University, Republic of Uzbekistan
8 Department of English Languages, Jizzakh State Pedagogical University, Uzbekistan
9 Bukhara State Pedagogical Institute, Uzbekistan
10 Department of Social and Humanitarian Sciences, Pedagogy and Psychology, Andijan State Institute of Foreign Languages, Republic of Uzbekistan
11 Department of “Nuclear Medicine and Medical Radiology”, Bukhara State Medical Institute, Bukhara, Uzbekistan
12 Department of Epidemilogy, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
13 Department of Epidemilogy, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
doi
10.22052/JNS.2025.03.059چکیده
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, demanding innovative therapeutic strategies with enhanced efficacy and reduced side effects. This study presents the development and optimization of solid lipid nanoparticles (SLNs) co-loaded with paclitaxel (PAC) and quercetin (QCT) for improved pulmonary cancer therapy. Seven formulations were prepared using stearic acid and Tween 80, with PAC and QCT concentrations ranging from 30 to 70 mg. Particle size analysis revealed diameters between 191.84 nm and 261.08 nm, with polydispersity indices (PDI) spanning 0.162 to 0.296, indicating narrow distribution and formulation stability. Zeta potential values ranged from −18.2 mV to −22.5 mV, suggesting adequate surface charge for colloidal dispersion. Encapsulation efficiencies for PAC and QCT were consistently high, reaching up to 96.92 ± 2.96% and 93.76 ± 3.04%, respectively. Among tested formulations, those with higher surfactant concentrations and balanced drug ratios demonstrated optimal physicochemical performance. To investigate release dynamics, five kinetic models—Zero-order, First-order, Higuchi, Hixson–Crowell, and Korsmeyer–Peppas—were applied to in vitro data. PAC-QCT-SLNs exhibited superior fit to the Higuchi model (R² = 0.9710), indicating a diffusion-controlled mechanism. The Korsmeyer–Peppas model showed the highest correlation (R² = 0.9916) with a release exponent n = 0.45, confirming non-Fickian transport. These results affirm the synergistic and sustained release behavior of dual-loaded SLNs. Overall, PAC–QCT-SLNs displayed enhanced encapsulation, controlled drug release, and favorable kinetic properties, highlighting their potential as a promising nanocarrier system for targeted lung cancer therapy.
